Society Letters

Comments on Medicare Model Guidelines Version 8.0

November 01, 2019

ATTN: United States Pharmacopeia

"When Congress enacted Medicare Part D, there were no widely accepted FDA-approved obesity drugs on the market. This fact, combined with the outdated misperception by many on Capitol Hill at that time that obesity was a lifestyle condition, led Congress to exclude Medicare Part D from covering “weight loss drugs.” Throughout this decade, significant medical advances have been made in the development of obesity drugs. These new medications and our country’s current and growing obesity epidemic clearly make the Part D statute no longer reflective of current scientific guidelines or current FDA approvals..."

arrow Read the Full Letter

Last Updated:
Take Action

Make Your Voice Heard

Take Action
We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.